Literature DB >> 18657147

The role of evidence-based medicine and clinical trials in rare genetic disorders.

M C Kruer1, R D Steiner.   

Abstract

The drive to empirically evaluate and analyze tools for the screening, diagnosis, management and monitoring of disease captured by the phrase 'evidence-based medicine (EBM)' has firmly entrenched itself as part of standard clinical care. However, rare genetic disorders, by their very nature, challenge the generation and application of EBM. This review presents many of the challenges encountered in applying EBM to rare genetic disorders, highlighting areas of recent emphasis in establishing multi-institutional collaborative research networks and in the systematic evaluation of developing therapies. Resources for identifying EBM tools for the practitioner are discussed, and the features and limitations of such resources are presented. Although the application of EBM to rare genetic disorders has definite limitations, a foundation has been established, and ongoing efforts seeking to systematically summarize and critically evaluate available evidence will continue to help identify the most effective tools for screening, diagnosis, management, and monitoring.

Entities:  

Mesh:

Year:  2008        PMID: 18657147     DOI: 10.1111/j.1399-0004.2008.01041.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  5 in total

Review 1.  Towards an evidence-based process for the clinical interpretation of copy number variation.

Authors:  E R Riggs; D M Church; K Hanson; V L Horner; E B Kaminsky; R M Kuhn; K E Wain; E S Williams; S Aradhya; H M Kearney; D H Ledbetter; S T South; E C Thorland; C L Martin
Journal:  Clin Genet       Date:  2011-12-13       Impact factor: 4.438

2.  Psychosexual development in men with congenital hypogonadotropic hypogonadism on long-term treatment: a mixed methods study.

Authors:  Andrew A Dwyer; Richard Quinton; Nelly Pitteloud; Diane Morin
Journal:  Sex Med       Date:  2015-03       Impact factor: 2.491

3.  Developing and evaluating rare disease educational materials co-created by expert clinicians and patients: the paradigm of congenital hypogonadotropic hypogonadism.

Authors:  Corin Badiu; Marco Bonomi; Ivan Borshchevsky; Martine Cools; Margarita Craen; Cristina Ghervan; Michael Hauschild; Eli Hershkovitz; Erik Hrabovszky; Anders Juul; Soo-Hyun Kim; Phillip Kumanov; Beatriz Lecumberri; Manuel C Lemos; Vassos Neocleous; Marek Niedziela; Sandra Pekic Djurdjevic; Luca Persani; Franziska Phan-Hug; Duarte Pignatelli; Nelly Pitteloud; Vera Popovic; Richard Quinton; Nicos Skordis; Neil Smith; Magdalena Avbelj Stefanija; Cheng Xu; Jacques Young; Andrew A Dwyer
Journal:  Orphanet J Rare Dis       Date:  2017-03-20       Impact factor: 4.123

4.  Development and validation of COMPASS: clinical evidence of orphan medicinal products - an assessment tool.

Authors:  Eline Picavet; David Cassiman; Bert Aertgeerts; Steven Simoens
Journal:  Orphanet J Rare Dis       Date:  2013-10-09       Impact factor: 4.123

5.  Identifying the unmet health needs of patients with congenital hypogonadotropic hypogonadism using a web-based needs assessment: implications for online interventions and peer-to-peer support.

Authors:  Andrew A Dwyer; Richard Quinton; Diane Morin; Nelly Pitteloud
Journal:  Orphanet J Rare Dis       Date:  2014-06-11       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.